Perspectives
David Lassen Shares Insights on Prime/MRx Analysis on GLP-1 for Weight Loss in New Video
October 31, 2023Earlier this year, Prime Therapeutics/Magellan Rx (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.
WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study
As GLP-1a drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.
Related news
Perspectives
May 15, 2024
High-Cost Therapy Profile
Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV)
Perspectives
May 15, 2024
June 2024 decisions expected from the FDA
Your monthly synopsis of new drugs expected to hit the market
Perspectives
May 15, 2024
Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
Approximately 83,000 new bladder cancer cases are diagnosed in the U.S. in each year. Here’s a look at the recent advancements and treatment options for bladder cancer, as well as an update on the BCG shortage.